Page 71 of 210: studies 701 to 710 of 2,096, newest first. Back to the PTSD overview
Military Medicine February 1, 1991
Pharmacologic treatment of patients with post-traumatic stress disorder often involves antidepressant drugs. Combat nightmares often persist. The addition of cyproheptadine, in a median dose of 16-24 mg orally at night, controls the nightmares.
Journal of Addiction Medicine Dafna Sara Rubin-Kahana, Ahmed Nabeel Hassan, Bernard Le Foll
In the last 2 decades, there is a renaissance in the scientific investigation of the therapeutic potential of psychedelic compounds. It is studied for the treatment of many psychiatric disorders, including posttraumatic stress disorder. The treatment is always done in the setting of psychedelic-assisted psychotherapy. A little is known about the potential effects, outside of the setting of...
Aaron Emile Philipp-Muller, Taras Reshetukha, Gustavo Vazquez et al.
BACKGROUND Over one third of patients with posttraumatic stress disorder (PTSD) do not respond to current interventions. Ketamine presents a potential treatment option; however, its effects are temporary. Administering ketamine alongside psychotherapy is one potential means of prolonging its effects; however, only a few studies have investigated this treatment method to date, and none have...
Michael Alvear preprint
Ketamine has emerged as a plausible rapid-acting treatment for post-traumatic stress disorder (PTSD), but the clinical literature is unusually easy to overstate because a small number of randomized trials are repeatedly represented across reviews, several publications reuse the same cohorts, and treatment studies are sometimes mixed with PTSD-prevention studies conducted around acute trauma....
Melina Schwab, Ulrich Weger, Terje Sparby preprint
Abstract There is ongoing research on the effect of meditation in the context of post-traumatic stress disorder (PTSD) and possible effects are the subject of controversial debate. The studies predominantly provide evidence of a beneficial effect, but possible risk factors also appear to be associated with meditation interventions. The impact of meditation on the process of psychotherapeutic...
Preprints.org Kainat Riaz, Sejal Suneel, Mohammad Hamza Bin Abdul Malik et al. 1 citation preprint
Post-traumatic stress disorder (PTSD) is a debilitating mental health disorder that causes significant dysfunction in individuals. Currently, there are many approved Pharmacotherapy and Psychotherapy treatment options for PTSD, but unfortunately, half of the patients do not respond to traditional therapies. In this article, we reviewed clinical trials and research on...
medRxiv Warwick M. Green, Sanket B Raut, F.l.j. James et al. 4 citations preprint
Abstract Post-Traumatic Stress Disorder (PTSD) causes broad impairments affecting quality of life. However, despite current treatment many people with PTSD do not fully recover. MDMA assisted psychotherapy has emerged as a new therapy for PTSD and its comorbidities. We aimed to analyse the current evidence for MDMA assisted psychotherapy in PTSD and associated quality of life, and physiological...
Philip Gerrans, Hugh Mgovern, Jakob Hohwy et al. 1 citation preprint
Complex post-traumatic stress disorder (C-PTSD) is a newly recognized diagnosis that is distinguished from post-traumatic stress disorder (PTSD) through additional symptom clusters beyond re-experiencing, avoidance, and a persistent sense of threat. In addition to these core PTSD symptoms, C-PTSD is characterized by disturbances in self-organization, including affective dysregulation, negative...
Noam Goldway, Taly Markovits, Naomi Fine et al. preprint
Dissociation, an altered state of consciousness in which individuals feel detached from their body, environment, and sense of self, is a common feature of Post-Traumatic Stress Disorder (PTSD). Despite its significance, the neurocognitive processes underlying dissociation remain poorly understood, potentially limiting the effectiveness of PTSD diagnostics and treatment. To address this gap, we...
Acacia C Parks, Amanda L Woodward, Robert D Henry et al.
BACKGROUND Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Post-Traumatic Stress Disorder (PTSD) are leading global causes of disability. Standard interventions often suffer from slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine have emerged as rapid-acting alternatives, their high cost and...